Binding of cis-dichlorodiammine platinum(II) to metallothionein in Ehrlich cells

https://doi.org/10.1016/0006-291X(85)90485-1Get rights and content

Abstract

The antitumor agent, cis-dichlorodiammine Pt(II), is cytotoxic to Ehrlich cells in culture. These cells contain a substantial amount of metallothionein in the absence of inducers of the protein. At concentrations of drug which cause 60% inhibition of cell proliferation, most of the platinum is found in the cytosol. Of this about 30% is bound in the metallothionein fraction. Isolated rat liver metallothionein reacts slowly with hydrolyzed cis-dichlorodiammine Pt(II). Thus, metallothionein is a major cellular site of binding of the platinum complex at concentrations which inhibit tumor growth.

References (24)

  • N.P. Johnson et al.

    Chem. Biol. Interactions

    (1980)
  • R.C. Manaka et al.

    Chem. Biol. Interactions

    (1978)
  • D.D. Choie et al.

    Toxicol. Appl. Pharmacol

    (1980)
  • R.P. Sharma et al.

    Biochem. Pharmacol

    (1983)
  • A.J. Zelazowski et al.

    Arch. Biochem. Biophys

    (1984)
  • A. Bakka et al.

    Toxicol. Appl. Pharmacol

    (1981)
  • G.L. Ellman

    Arch. Biochem. Biophys

    (1959)
  • B. Rosenberg
  • J.M. Pascoe et al.

    Biochem. Pharmacol

    (1974)
  • W. Wolf et al.

    J. Clin. Hematol. and Oncol

    (1977)
  • J. Koch et al.

    Biochem. J

    (1980)
  • A.J. Kraker et al.

    Biol. Tr. Ele. Res

    (1983)
  • Cited by (63)

    • Metallothioneins

      2021, Comprehensive Coordination Chemistry III
    • Effect of chirality in platinum drugs

      2015, Coordination Chemistry Reviews
      Citation Excerpt :

      Thus, the transcriptional profiling approach can represent a unique tool for investigating differences between antitumor drugs belonging to the same family such as cisplatin and oxaliplatin or oxaliplatin and its S,S-enantiomer. Although scientists have initially focused on the characterization of platinum-DNA interaction [31], protein-bound platinum represents the most part of administered drug in the case of cisplatin, both in the extracellular medium (up to 98% of cisplatin interacts with albumin) [32] and into the cytoplasm [33], binding to S-donors being markedly favored [34]. Reactions occurring with cytosolic components are generally retained responsible for the broad spectrum of side effects [35], and contribute to resistance [36].

    • The role of metallothionein in oncogenesis and cancer prognosis

      2009, Progress in Histochemistry and Cytochemistry
    View all citing articles on Scopus
    View full text